Patents by Inventor Charles Y. F. Young

Charles Y. F. Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090036544
    Abstract: The invention provides for methods of monitoring the proliferation of cultured prostate cancer cells in the presence of POH, methods of treating an individual with prostate cancer or at risk of developing prostate cancer, and methods of reducing the risk of recurrence of prostate cancer in an individual who had previously been treated for prostate cancer. Methods of the invention further include treating an individual with benign prostatic hyperplasia (BPH) with POH as well as methods of screening for compounds that inhibit the proliferation of prostate cancer cells. The invention provides for compositions and articles of manufacture containing POH in particular formulations, and POH with a second compound that also exerts an effect on the androgen receptor.
    Type: Application
    Filed: October 18, 2007
    Publication date: February 5, 2009
    Inventor: Charles Y. F. Young
  • Publication number: 20040259113
    Abstract: Prostrate cancer is detected by determining the presence of hK2 polypeptide of hK2 RNA in a physiological sample.
    Type: Application
    Filed: December 23, 2003
    Publication date: December 23, 2004
    Applicant: Mayo Foundation for Medical Education and Research, Hybritech Incorporated
    Inventors: Donald J. Tindall, Charles Y. F. Young
  • Publication number: 20030113743
    Abstract: Prostate cancer is detected by determining the presence of hK2 RNA in a physiological sample.
    Type: Application
    Filed: April 22, 2002
    Publication date: June 19, 2003
    Applicant: Baylor College of Medicine, Hybritech Incorporated
    Inventors: Kevin M. Slawin, Donald J. Tindall, Charles Y.F. Young
  • Patent number: 6479263
    Abstract: Prostate cancer is detected by determining the presence of hK2 RNA in a physiological sample.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: November 12, 2002
    Assignees: Baylor College of Medicine, Mayo Foundation for Medical Education and Research
    Inventors: Kevin M. Slawin, Donald J. Tindall, Charles Y. F. Young, Mohammad Saeed Saedi, Abhay Kumar, Harry G. Rittenhouse, Robert L. Wolfert
  • Patent number: 6235486
    Abstract: Breast cancer is detected by determining the presence of hK2 polypeptide or hK2 RNA in a physiological sample.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: May 22, 2001
    Assignee: Mayo Foundation for Medical Education & Research
    Inventors: Charles Y. F. Young, Donald J. Tindall, George G. Klee
  • Patent number: 6093796
    Abstract: An isolated, substantially homogenous pre-pro, pro or mature hK2 polypeptide is provided as well as biologically active variants or subunits thereof, including a biologically active variant pre-pro hK2 polypeptide having SEQ ID NO:19.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: July 25, 2000
    Assignees: Mayo Foundation for Medical Education and Research, Hybritech Incorporated
    Inventors: Donald J. Tindall, Charles Y. F. Young, Mohammad Saeed Saedi, Stephen D. Mikolajczyk
  • Patent number: 6013471
    Abstract: Isolated nucleic acid molecules encoding variant hK2 polypeptides and fragments thereof, as well as expression cassettes and host cells comprising said nucleic acid molecules, are provided. Also provided is a method to express a nucleic acid molecule encoding a variant hK2 polypeptide.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: January 11, 2000
    Assignees: Hybritech Incorporated, Mayo Foundation for Medical Education and Research
    Inventors: Donald J. Tindall, Charles Y. F. Young, Mohammad Saeed Saedi, Abhay Kumar
  • Patent number: 5516639
    Abstract: The present invention provides an isolated preparation of monoclonal or polyclonal antibodies which react specifically with human prostate-specific glandular kallikrein (hK2), but which do not cross-react with human prostate-specific antigen (PSA), as well as immunogenic hK2 antigens useful to provide such antibodies.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: May 14, 1996
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Donald J. Tindall, Charles Y. F. Young, George G. Klee